文献速递造血干细胞移植与细胞治疗

HLA-DRB3/4/5错配与10/10相合无关供者造血细胞移植中急性GVHD风险增加相关

HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation.
PubMed 文献 · Am J Hematol · 2018-05-04

该研究纳入2000至2012年法国1975例接受首次10/10相合无关供者造血细胞移植的血液恶性肿瘤患者,所有供受者均进行HLA-A、-B、-C、-DRB1、-DQB1、-DPB1及-DRB3/4/5高分辨率分型。慢性GVHD、非复发死亡、复发及总生存无差异。作者认为无关供者选择时考虑DRB3/4/5位点可能使患者获益以改善GRFS及移植后生活质量。

要点

  • 10/10相合无关供者移植中,DRB3/4/5错配与II-IV级急性GVHD风险显著增加相关(校正HR 1.43)。
  • DRB3/4/5错配与GRFS更差相关(校正HR 1.20),慢性GVHD、非复发死亡、复发及总生存无差异。
  • 作者认为无关供者选择时考虑DRB3/4/5位点可能改善GRFS及移植后生活质量。

核心结论

  • 慢性GVHD、非复发死亡、复发及总生存方面未观察到差异。
  • 作者认为无关供者选择时考虑DRB3/4/5位点可能使患者获益,以改善GRFS及移植后生活质量。

研究设计与样本

  • 研究纳入2000至2012年在法国接受首次10/10相合无关供者造血细胞移植的1975例血液恶性肿瘤患者。
  • 对所有供受者配对进行HLA-A、-B、-C、-DRB1、-DQB1、-DPB1及-DRB3/4/5位点高分辨率分型。

主要发现

  • 慢性GVHD、非复发死亡、复发及总生存方面未观察到差异。

临床怎么用

  • 作者认为无关供者选择时考虑DRB3/4/5位点可能使患者获益,以改善GRFS及移植后生活质量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Matching for HLA-A, -B, -C, and -DRB1 loci (8/8 match) is currently the gold standard for unrelated donor hematopoietic cell transplantation (HCT). In Europe, patients are also matched at the HLA-DQB1 loci (10/10 match). However, there is increasing evidence that matching at HLA-DRB3/4/5 loci may help to lower transplant-related morbidity and mortality. We therefore investigated the impact of HLA-DRB3/4/5 mismatches on outcomes in 1975 patients who received a first 10/10 matched unrelated donor (MUD) HCT in France from 2000 to 2012 for a hematological malignancy. High-resolution typing was performed at HLA-A, -B, -C, -DRB1, -DQB1, -DPB1, and -DRB3/4/5 loci for all donor/recipient pairs. Compared with DRB3/4/5-matched pairs, patients who received a MUD HCT from a DRB3/4/5 mismatched donor had a significantly increased risk of grade II-IV acute graft-versus-host disease (aGVHD) (Adjusted Hazard Ratio (HR) 1.43 (1.07 to 1.90)) associated with lower graft-versus-host disease-free and relapse-free survival (GRFS) (Adjusted HR 1.20 (1.02 to 1.42)). Conversely, we observed no differences in terms of chronic GVHD, nonrelapse mortality, relapse and overall survival. However, we believe that patients stand to benefit from DRB3/4/5 loci being considered for unrelated donor selection to improve GRFS and then quality of life after unrelated HCT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ducreux S, Dubois V, Amokrane K, et al. HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation. Am J Hematol. 2018. PMID: 29726580. doi:10.1002/ajh.25133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。